Ligand Pharmac-B (LGND.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov7

Benchmark Co. and H.C. Wainwright Maintain Buy Ratings for Ligand Pharma

12:42

Nov6

Ligand Pharmac-B released FY2025 Q3 earnings on November 6 Pre-Market (EST), actual revenue USD 115.46 M (forecast USD 58.05 M), actual EPS USD 5.68 (forecast USD 1.0466)

14:30

Ligand Pharmac-B released FY2025 9 Months earnings on November 6 Pre-Market (EST), actual revenue USD 208.42 M, actual EPS USD 3.7079

14:30

Oct30

Ligand Pharmac-B to Release FY2025 Q3 Earnings on November 6, Pre-Market EST; Forecast Revenue USD 58.71 M, EPS USD 1.0657

00:39

Oct3

Ligand Pharmaceuticals Director John W. Kozarich Sells Common Stock

20:46

Sep5

Oppenheimer Raises Ligand's Price Target to $190

05:18

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 115.46 M, Net Income 117.27 M, EPS 5.68

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 47.63 M, Net Income 4.847 M, EPS 0.24

May8

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 45.33 M, Net Income -42.45 M, EPS -2.212

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change